E-cigarette vapour does not damage DNA, even at doses 28 times that of equivalent smoke exposure.
Several studies have compared the impact of e-cigarette vapour with that of cigarette smoke on cells and found that vapour has little or no effect.
New research proves that e-cigarette aerosol droplets are effectively delivered to cell surfaces in lab-based biological tests.
New research shows that e-cigarettes are as effective at delivering nicotine as conventional cigarettes, especially when used by experienced vapers.
BAT has won the award for the ‘Most Impressive Public Service Initiative’ at the Global Tobacco and Nicotine Forum (GTNF) conference in Brussels.
US-based biotech company IONTOX and British American Tobacco have entered into a collaboration to develop a lung-liver-lung model with a simulated blood system to study the impact of tobacco and nicotine products on lung health.
Understanding vaping behaviour is an essential first step towards understanding how vaping products are being used by consumers and the potential they may have to reduce harm caused by smoking.
Recent tests conducted by scientists at British American Tobacco (BAT) show that, in stark contrast to cigarette smoke, vapour from the commercially available e-cigarette Vype ePen is less toxic to, and does not cause oxidative stress1 in, human lung cells.
A comparison between the vapour from Vype ePen – a commercially available e-cigarette – and 3R4F – a reference cigarette – revealed substantial reductions in the e-Pen’s emissions for all toxicant groups measured.
Against a backdrop of a growing number of e-cigarette users globally*, British American Tobacco (BAT) is leading efforts to develop and harmonise standards around vaping products to further reassure consumers of these products potential in reducing the harm from smoking.
A culture of greater—not less— transparency in tobacco and tobacco-industry funded research is needed if we are to realise the reduced risk potential of e-cigarettes and other next generation products.
The impact of e-cigarettes was recently explored in BBC’s Horizon documentary, E-cigarettes: Miracle or Menace?, which concluded that e-cigarettes could benefit public health.
BAT presented its experience and approach to using biomarkers to assess the reduced-risk potential of novel tobacco and nicotine products at the US Food and Drug Administration’s workshop Biomarkers of Potential Harm (April 4-5).
BAT’s Pre-Clinical Assessment Manager, Dr Marinna Gaça, presented on Acute inhalation toxicity: in vitro and ex vivo systems in a webinar covering State-of-the-science, practical application, and dosimetry considerations for in vitro and ex vivo methods.
A regulatory mechanism that allows for a bridging approach between different variants of e-cigarettes and other next generation products is needed.
In-vitro testing of Vype vapour revealed no cell stress, DNA damage or malignant transformation.
BAT’s Chief Scientific Officer, Chris Proctor, is in San Diego at the Spring National Meeting of the American Chemical Society.
Hybrid device produces tobacco-flavoured aerosol with same characteristics as e-cigarette vapour.
Available today, British American Tobacco’s 2015 Science & Technology Report details significant strides in the science of tobacco harm reduction made by BAT’s R&D department over the last year.
Formaldehyde exposure from three different e-cigarette formats well below WHO air quality guideline.